Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood Jg. 130; H. 25; S. 2709
Hauptverfasser:	Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L, Rosenblatt, Joseph D, Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M, Fenton, Keenan, Huebner, Dirk, Pinelli, Juan M, Kennedy, Dana A, Shustov, Andrei
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 21.12.2017
Schlagworte:	Adolescent Adult Aged Brentuximab Vedotin Disease Progression Disease-Free Survival Female Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Longitudinal Studies Lymphoma, Large-Cell, Anaplastic - complications Lymphoma, Large-Cell, Anaplastic - drug therapy Lymphoma, Large-Cell, Anaplastic - pathology Male Middle Aged Peripheral Nervous System Diseases - etiology Remission Induction Salvage Therapy - methods Stem Cell Transplantation Survival Analysis Treatment Outcome Young Adult
ISSN:	1528-0020, 1528-0020
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (n = 58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16 patients, 8 received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, which demonstrated a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047.
AbstractList	This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (n = 58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16 patients, 8 received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, which demonstrated a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047.This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (n = 58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16 patients, 8 received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, which demonstrated a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047. This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (n = 58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16 patients, 8 received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, which demonstrated a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047.
Author	Rosenblatt, Joseph D Matous, Jeffrey Ramchandren, Radhakrishnan Pinelli, Juan M Fenton, Keenan Fanale, Michelle Shustov, Andrei Pro, Barbara Advani, Ranjana Bartlett, Nancy L Kennedy, Dana A Brice, Pauline Huebner, Dirk Connors, Joseph M Illidge, Tim
Author_xml	– sequence: 1 givenname: Barbara surname: Pro fullname: Pro, Barbara organization: Robert H. Lurie Comprehensive Cancer Center, Chicago, IL – sequence: 2 givenname: Ranjana surname: Advani fullname: Advani, Ranjana organization: Division of Oncology, Stanford University Medical Center, Palo Alto, CA – sequence: 3 givenname: Pauline surname: Brice fullname: Brice, Pauline organization: Hemato-oncology Department, Hospital Saint-Louis, Paris, France – sequence: 4 givenname: Nancy L surname: Bartlett fullname: Bartlett, Nancy L organization: Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO – sequence: 5 givenname: Joseph D surname: Rosenblatt fullname: Rosenblatt, Joseph D organization: Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 6 givenname: Tim surname: Illidge fullname: Illidge, Tim organization: Christie Hospital National Health Service, Manchester, United Kingdom – sequence: 7 givenname: Jeffrey surname: Matous fullname: Matous, Jeffrey organization: Colorado Blood and Cancer Institute, Denver, CO – sequence: 8 givenname: Radhakrishnan surname: Ramchandren fullname: Ramchandren, Radhakrishnan organization: Karmanos Cancer Institute, Detroit, MI – sequence: 9 givenname: Michelle surname: Fanale fullname: Fanale, Michelle organization: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 10 givenname: Joseph M surname: Connors fullname: Connors, Joseph M organization: British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada – sequence: 11 givenname: Keenan surname: Fenton fullname: Fenton, Keenan organization: Seattle Genetics, Inc, Bothell, WA – sequence: 12 givenname: Dirk surname: Huebner fullname: Huebner, Dirk organization: Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceuticals Limited; and – sequence: 13 givenname: Juan M surname: Pinelli fullname: Pinelli, Juan M organization: Seattle Genetics, Inc, Bothell, WA – sequence: 14 givenname: Dana A surname: Kennedy fullname: Kennedy, Dana A organization: Seattle Genetics, Inc, Bothell, WA – sequence: 15 givenname: Andrei surname: Shustov fullname: Shustov, Andrei organization: Division of Hematology, University of Washington School of Medicine, Seattle, WA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28974506$$D View this record in MEDLINE/PubMed
BookMark	eNpNkE9LxDAQxYOsuH_0G4jk6KWaZNMmPcriqrDgRc9L0kzcStrUJF23394uriAMzIP5zfDmzdGk9S0gdE3JHaWS3WvnvckYoSIjeSYkIbw8QzOaM5kRwsjkn56ieYyfhFC-ZPkFmjJZCp6TYoYO63oP2QAq4ACxdylib7EO0Kb-UDdK4z0Yn-oWj9WpVI-DiL_rtBt5p7oIBvvjrg2qSj4MOA4xQVNXWLWqcyqmUToVPgBX4Bx2Q9PtfKMu0blVLsLVqS_Q-_rxbfWcbV6fXlYPm6zixTKN_1WMUU6NYcKWnFiQVBuiTaUpgGTcUEl4IXMwWubUitJoKy3lhGmhQbAFuv292wX_1UNM26aORyeqBd_HLS25IGW5LIoRvTmhvW7AbLswBhCG7V9a7AeOKHJ4
CitedBy_id	crossref_primary_10_12688_f1000research_22257_1 crossref_primary_10_5306_wjco_v12_i10_882 crossref_primary_10_1080_17474086_2021_1942831 crossref_primary_10_1111_bjh_15783 crossref_primary_10_1016_j_jaapos_2024_104098 crossref_primary_10_1016_j_blre_2020_100653 crossref_primary_10_1080_10428194_2025_2545927 crossref_primary_10_3390_jpm12060964 crossref_primary_10_1016_j_clml_2025_05_009 crossref_primary_10_1038_s41375_020_0789_x crossref_primary_10_1007_s12325_021_01943_z crossref_primary_10_1016_j_annonc_2025_01_023 crossref_primary_10_3390_jpm11060481 crossref_primary_10_1182_blood_2017_12_821009 crossref_primary_10_1080_10428194_2020_1839658 crossref_primary_10_1080_17474086_2019_1558399 crossref_primary_10_3389_fonc_2023_1301437 crossref_primary_10_7759_cureus_84058 crossref_primary_10_1158_1078_0432_CCR_24_1913 crossref_primary_10_1007_s12185_020_03039_w crossref_primary_10_1007_s11912_020_00902_1 crossref_primary_10_1111_bjh_17951 crossref_primary_10_1002_hem3_70128 crossref_primary_10_1007_s12185_020_02863_4 crossref_primary_10_1186_s13045_020_00892_4 crossref_primary_10_1097_GOX_0000000000002188 crossref_primary_10_1002_cam4_4052 crossref_primary_10_1053_j_seminhematol_2021_02_006 crossref_primary_10_1182_blood_2020009806 crossref_primary_10_3390_ijms20030552 crossref_primary_10_1016_j_revmed_2020_05_015 crossref_primary_10_1182_bloodadvances_2023011470 crossref_primary_10_1097_CMR_0000000000000702 crossref_primary_10_1038_s41409_019_0734_7 crossref_primary_10_1016_S0140_6736_18_32984_2 crossref_primary_10_1097_SAP_0000000000002910 crossref_primary_10_1016_j_jtos_2021_06_007 crossref_primary_10_3389_fonc_2021_718590 crossref_primary_10_1182_bloodadvances_2023012129 crossref_primary_10_3390_md18120619 crossref_primary_10_7759_cureus_71430 crossref_primary_10_1016_j_leukres_2018_12_008 crossref_primary_10_1002_cnr2_1377 crossref_primary_10_1002_jha2_70041 crossref_primary_10_1007_s00277_018_3288_7 crossref_primary_10_1111_bjh_20154 crossref_primary_10_3389_fonc_2023_1242552 crossref_primary_10_3390_cancers13020295 crossref_primary_10_1007_s11899_023_00710_x crossref_primary_10_1016_j_clml_2024_11_015 crossref_primary_10_1038_s41375_023_02038_0 crossref_primary_10_1182_bloodadvances_2023012531 crossref_primary_10_1016_j_clml_2019_03_001 crossref_primary_10_1111_bjh_17896 crossref_primary_10_1182_blood_2019002799 crossref_primary_10_1097_MD_0000000000025576 crossref_primary_10_1111_bjh_18467 crossref_primary_10_1182_bloodadvances_2021004424 crossref_primary_10_3390_cancers13236003 crossref_primary_10_3390_cancers13236125 crossref_primary_10_1002_hon_3191 crossref_primary_10_2147_OTT_S487088 crossref_primary_10_1177_20406207221143025 crossref_primary_10_3390_cancers10040114 crossref_primary_10_1016_j_leukres_2019_05_014 crossref_primary_10_1177_20406207211048959 crossref_primary_10_1002_hon_2702 crossref_primary_10_1186_s13045_021_01033_1 crossref_primary_10_1634_theoncologist_2017_0524 crossref_primary_10_3389_fimmu_2023_1203471 crossref_primary_10_3390_cancers15030589 crossref_primary_10_1016_j_jconrel_2022_01_017 crossref_primary_10_1080_1744666X_2020_1732819 crossref_primary_10_1016_j_beha_2023_101444 crossref_primary_10_1016_j_jaad_2024_08_036 crossref_primary_10_1111_bjh_15742 crossref_primary_10_1007_s44178_023_00063_8 crossref_primary_10_1016_j_beha_2023_101442 crossref_primary_10_1111_his_13932 crossref_primary_10_1016_j_bjps_2025_07_045 crossref_primary_10_3390_cancers15245733 crossref_primary_10_3390_cancers14092332 crossref_primary_10_1021_jacs_7b13361 crossref_primary_10_1111_imj_15595 crossref_primary_10_3390_ijms222011079 crossref_primary_10_1002_cncr_32697 crossref_primary_10_3390_hematolrep17010003 crossref_primary_10_4252_wjsc_v13_i6_503 crossref_primary_10_1007_s11864_021_00873_w crossref_primary_10_3389_fonc_2024_1494384 crossref_primary_10_3390_cancers14061569 crossref_primary_10_7759_cureus_55258 crossref_primary_10_1007_s11899_018_0432_3 crossref_primary_10_1111_bjh_18841 crossref_primary_10_1007_s11899_018_0478_2 crossref_primary_10_1007_s12254_024_00965_x crossref_primary_10_1186_s13045_019_0786_6 crossref_primary_10_1016_j_critrevonc_2020_102981 crossref_primary_10_3389_fimmu_2023_1068662 crossref_primary_10_4081_hr_2020_8368 crossref_primary_10_1111_cas_14671 crossref_primary_10_3960_jslrt_25013 crossref_primary_10_1080_10428194_2023_2252945 crossref_primary_10_1136_bcr_2019_230641 crossref_primary_10_3390_cancers17030496 crossref_primary_10_3389_fphar_2022_869488 crossref_primary_10_1002_hon_2560 crossref_primary_10_1016_j_annemergmed_2024_10_015 crossref_primary_10_1016_j_ctrv_2024_102793 crossref_primary_10_1182_blood_2017_10_811083 crossref_primary_10_1080_14712598_2019_1572746 crossref_primary_10_1016_j_clml_2019_07_443 crossref_primary_10_3390_cancers17071134 crossref_primary_10_3390_cancers17071137 crossref_primary_10_3390_lymphatics1020012 crossref_primary_10_1038_s41409_019_0732_9 crossref_primary_10_1002_hon_2565 crossref_primary_10_5858_arpa_2021_0270_OA crossref_primary_10_3390_diagnostics11071220 crossref_primary_10_1007_s12325_019_01046_w crossref_primary_10_1080_17474086_2025_2492936 crossref_primary_10_1136_jitc_2020_001235 crossref_primary_10_1038_s41409_018_0378_z crossref_primary_10_1097_CCO_0000000000000469 crossref_primary_10_1182_bloodadvances_2025016199 crossref_primary_10_1080_21691401_2019_1709857 crossref_primary_10_1097_PPO_0000000000000452 crossref_primary_10_3389_fimmu_2024_1346001 crossref_primary_10_3390_cancers10090339 crossref_primary_10_3390_cancers13112679 crossref_primary_10_1080_14740338_2020_1718103 crossref_primary_10_3390_cancers15030925 crossref_primary_10_1016_j_phrs_2025_107628 crossref_primary_10_3389_fimmu_2024_1520103 crossref_primary_10_1002_hon_3142 crossref_primary_10_1007_s12015_020_10080_z crossref_primary_10_24287_1726_1708_2019_18_2_83_91 crossref_primary_10_1038_s41375_021_01191_8 crossref_primary_10_1182_blood_2019001821 crossref_primary_10_1007_s11899_020_00561_w crossref_primary_10_1002_cam4_6733 crossref_primary_10_1080_2162402X_2019_1625688 crossref_primary_10_1080_10428194_2023_2287965 crossref_primary_10_1182_bloodadvances_2024014745 crossref_primary_10_1002_ajh_27345 crossref_primary_10_1186_s13045_024_01560_7 crossref_primary_10_1016_j_tranon_2020_100913 crossref_primary_10_3389_fonc_2022_815654 crossref_primary_10_1038_s41409_020_0976_4 crossref_primary_10_1016_j_pharmthera_2020_107552 crossref_primary_10_1097_MPH_0000000000001914 crossref_primary_10_1016_j_leukres_2022_106794
ContentType	Journal Article
Copyright	2017 by The American Society of Hematology.
Copyright_xml	– notice: 2017 by The American Society of Hematology.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1182/blood-2017-05-780049
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Chemistry Biology Anatomy & Physiology
EISSN	1528-0020
ExternalDocumentID	28974506
Genre	Multicenter Study Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFETI AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS
ID	FETCH-LOGICAL-c463t-20c22141dd27f940fe81bd0bdcb1ee824d1804685edb851f79dbf8f1402b7be72
IEDL.DBID	7X8
ISICitedReferencesCount	188
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000418895900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1528-0020
IngestDate	Sun Nov 09 11:16:29 EST 2025 Wed Feb 19 02:30:38 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	25
Language	English
License	2017 by The American Society of Hematology.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c463t-20c22141dd27f940fe81bd0bdcb1ee824d1804685edb851f79dbf8f1402b7be72
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
OpenAccessLink	https://dx.doi.org/10.1182/blood-2017-05-780049
PMID	28974506
PQID	1947099366
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1947099366 pubmed_primary_28974506
PublicationCentury	2000
PublicationDate	2017-12-21 20171221
PublicationDateYYYYMMDD	2017-12-21
PublicationDate_xml	– month: 12 year: 2017 text: 2017-12-21 day: 21
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Blood
PublicationTitleAlternate	Blood
PublicationYear	2017
References	29269528 - Blood. 2017 Dec 21;130(25):2691-2692 30049735 - Blood. 2018 Jul 26;132(4):458-459
References_xml	– reference: 29269528 - Blood. 2017 Dec 21;130(25):2691-2692 – reference: 30049735 - Blood. 2018 Jul 26;132(4):458-459
SSID	ssj0014325
Score	2.6254823
Snippet	This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	2709
SubjectTerms	Adolescent Adult Aged Brentuximab Vedotin Disease Progression Disease-Free Survival Female Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Longitudinal Studies Lymphoma, Large-Cell, Anaplastic - complications Lymphoma, Large-Cell, Anaplastic - drug therapy Lymphoma, Large-Cell, Anaplastic - pathology Male Middle Aged Peripheral Nervous System Diseases - etiology Remission Induction Salvage Therapy - methods Stem Cell Transplantation Survival Analysis Treatment Outcome Young Adult
Title	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
URI	https://www.ncbi.nlm.nih.gov/pubmed/28974506 https://www.proquest.com/docview/1947099366
Volume	130
WOSCitedRecordID	wos000418895900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS-QwFH_4sbpeXB3d9WvlLcjegm2aNulJVBy8OHhQmNuQNAkMzLSjnRHnv9-XtoMnYUEooZeUkPf68nsfeT-Ai6TInXQ-ZUKHweucmcw4lheZTgxBEiVasgk5GKjhMH_sAm51V1a5somNobZVEWLkl-RsS5qaZNnV7IUF1qiQXe0oNNZhMyEoE7RaDj-yCCJpSFfpiFIs4KLu6hxB6su2LJwHGx2lTKqAlD8Hmc1h0__x1WXuwW4HM_G61Yt9WHNlDw6uS3Kxp0v8i03hZxNR78HWzert--2K_q0H2w9d1v0A3vtkEtmS_gkk53wxmddYeTShr9PifTzVBt8cObfjEunpGrXWGCK8GK7KzGpnsQpz_WvD7rPEtn_0uEBd6hnhd1olTkJNOoZEAk6WpGPVVB_Cc__u6faedYwNrBBZMqf9LDiPRWwtlz4XkXeEim1kbGFi5xQXNlbkkKvUWUNQz8vcGq88OXncSOMk_wkbZVW6I8DQpEcaneQZN0JFLo9TKzV9SxhvCEMdw5-VAEa0M2F1unTVoh59iOAYfrVSHM3a1h0jci-lSKPs5D9mn8JOox8xZzw-g01P9sD9hm_F23xcv543qkbj4PHhH3Oz4Go
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Five-year+results+of+brentuximab+vedotin+in+patients+with+relapsed+or+refractory+systemic+anaplastic+large+cell+lymphoma&rft.jtitle=Blood&rft.au=Pro%2C+Barbara&rft.au=Advani%2C+Ranjana&rft.au=Brice%2C+Pauline&rft.au=Bartlett%2C+Nancy+L&rft.date=2017-12-21&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=130&rft.issue=25&rft.spage=2709&rft_id=info:doi/10.1182%2Fblood-2017-05-780049&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon